Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that it has been accepted into the Stop TB Partnership. Designer Diagnostics, a wholly owned subsidiary of Nutra Pharma has also been accepted into the organization.
"We are honored to be accepted as a member of this partnership," commented Neil Roth, President of Designer Diagnostics. "It is our belief that Designer Diagnostics can play a vital role in ending tuberculosis. Our test kits can be used in harsh environments and without refrigeration, making it especially useful in the third world countries in Africa and South Asia, where the disease is most prevalent," he explained.
The Stop TB Partnership was established in 2000 to realize the goal of eliminating tuberculosis (TB) as a public health problem and, ultimately, to obtain a world free of TB. It comprises a network of international organizations, countries, donors from the public and private sectors, governmental and nongovernmental organizations and individuals that have expressed an interest in working together to achieve this goal. TB kills 800,000 people annually. Although it is curable, it is one of the so-called opportunistic diseases associated with HIV/AIDS. The Stop TB Partnership is a consortium of 480 organizations around the world that are working towards completely eradicating this fatal disease.
"It is vital to the future of the Company to be involved in global missions such as the Stop TB Partnership," said Rik J Deitsch, Nutra Pharma's Chief Executive Officer. "As we educate the global community on the necessity of using these diagnostic kits, we will have a profound impact in Asia and Africa. This also goes hand-in-hand with our drug development in finding ways to combat diseases like HIV," he added.
For more information on the Stop TB Partnership, visit their website at: www.StopTB.org.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Being accepted into the Stop TB Partnership should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.